Clinical value of prostate-specific antigen combined with tumor abnormal protein (TAP) in the diagnosis of prostate puncture

BACKGROUND: In this study, we aimed to test the clinical value of total prostate-specific antigen (T-PSA), free prostate-specific antigen (F-PSA), and T-PSA combined with tumor abnormal glycoprotein (TAP) for early diagnosis of prostate cancer. METHODS: The levels of serum T-PSA and F-PSA were measured in 105 malignant prostate tumors and 97 benign prostate tissues using chemiluminescence immunoassay. The concentration of TAP in the serum of patients was tested by the agglutination method. Differences in PSA levels and F-PSA/T-PSA ratio in two patient groups were analyzed by t-test. TAP concentrations were compared using Chi-square test. The sensitivity, specificity, and accuracy of PSA combined with TAP for the diagnosis of prostate cancer were analyzed. RESULTS: The serum PSA level in patients with malignant tumors were higher than that in patients with benign tumors (P<0.0001). TAP positivity in patients with prostate cancer was higher than that in patients with benign tumors (P<0.0001). The number of cases with positive and weakly positive TAP values in three intervals of T-PSA concentrations was higher in patients with malignant tumors, while the number of negative cases was higher in patients with benign tumors (P<0.05). The sensitivity, specificity, and accuracy of T-PSA combined with TAP in the diagnosis of prostate cancer were 97.14%, 67.01%, and 81.68% respectively, which was higher compared to the other measured markers. CONCLUSIONS: The results of our study indicate that PSA combined with TAP is a sensitive, specific, and accurate diagnostic marker of prostate cancer. Therefore, it has potential clinical relevance for the early screening of prostate cancer.